Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline

J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30.

Abstract

After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.

Keywords: Human Papillomavirus Vaccine; Uterine Cervical Neoplasms.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Child
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / adverse effects
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / therapeutic use
  • Humans
  • Middle Aged
  • Papillomavirus Vaccines / administration & dosage
  • Papillomavirus Vaccines / adverse effects
  • Papillomavirus Vaccines / therapeutic use*
  • Practice Guidelines as Topic*
  • Republic of Korea
  • Treatment Outcome
  • Uterine Cervical Neoplasms / prevention & control*
  • Young Adult

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines
  • human papillomavirus vaccine, L1 type 16, 18